Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism?

ISSN： 0028-1298

Source： Naunyn-Schmiedeberg's Archives of Pharmacology, Vol.377, Iss.3, 2008-05, pp. : 205-207

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Incretin-Targeting Technologies for Type 2 Diabetes: Dipeptidyl Peptidase IV Inhibitors and Glucagon-Like Peptide-1 Analogs

By Adis International Limited

Pharmaceutical & Diagnostic Innovation, Vol. 4, Iss. 7, 2006-07 ,pp. : 3-7

Adis International

Access to resources Recommend Favorite

Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs

By Mentlein Rolf

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 1, 2005-01 ,pp. : 57-64

Informa Healthcare

Access to resources Recommend Favorite

Metformin increases the plasma level of glucagon-like peptide-1 (GLP-1) and does not inhibit dipeptidyl peptidase-IV

Inpharma, Vol. 1, Iss. 1607, 2007-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Treatment of Type 2 diabetes mellitus based on glucagon-like peptide-1

By Holst J.J.

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 9, 1999-09 ,pp. : 1409-1415

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

By Drucker DJ

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 1, 2003-01 ,pp. : 87-100

Informa Healthcare

Access to resources Recommend Favorite